Physician profile
Grigorios Chrysofakis
NPI 1700159118
$5,370.29
in general payments reported to CMS, 2019-2025
35 companies · $559 in 2025
The $559 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $43.63 · 2021: $616 · 2022: $1,388 · 2023: $1,243 · 2024: $1,374 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,903 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.33 |
| Education | $271.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $912.42 | 2019-2025 | |
| Astellas Pharma US INC | $689.30 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Seagen INC. | $345.92 | 2022-2023 | Adcetris, Padcev |
| Novartis Pharmaceuticals Corporation | $327.13 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $325.37 | 2020-2025 | Opdivo, Opdualag |
| Amgen INC. | $299.54 | 2021-2023 | Kyprolis, Lumakras |
| Genentech USA, INC. | $250.03 | 2020-2025 | Tecentriq, Polivy, Phesgo |
| Celgene Corporation | $237.84 | 2023-2025 | Reblozyl, Pomalyst, Onureg |
| Glaxosmithkline, LLC. | $197.78 | 2021-2025 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $191.95 | 2019-2025 | Keytruda, Welireg |
| Monteris Medical Corporation | $144.63 | 2025 | Neuroblate |
| Pharmacyclics LLC, An Abbvie Company | $134.55 | 2021-2022 | |
| Kite Pharma, INC. | $129.00 | 2021-2023 | Yescarta |
| Daiichi Sankyo INC. | $119.00 | 2021-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $113.76 | 2021-2024 | Erleada |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $97.00 | 2021-2025 | Braftovi, Lorbrena, Mektovi |
| Astrazeneca Pharmaceuticals Lp | $96.65 | 2024-2025 | Lynparza, Enhertu |
| Lilly USA, LLC | $91.47 | 2022-2023 | Verzenio, Jaypirca |
| Abbvie INC. | $83.83 | 2022-2024 | Venclexta |
| Deciphera Pharmaceuticals INC. | $76.61 | 2021-2024 | Qinlock |
| Eisai INC. | $67.22 | 2019-2025 | |
| Gilead Sciences, INC. | $62.72 | 2019-2023 | Trodelvy |
| Servier Pharmaceuticals LLC | $59.60 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $45.47 | 2022-2023 | Ultomiris |
| Sumitomo Pharma America, INC. | $39.71 | 2023 | Orgovyx |
| Ge Healthcare | $36.10 | 2022 | |
| Springworks Therapeutics, INC. | $30.07 | 2024 | Ogsiveo |
| Beigene USA, INC. | $26.43 | 2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $23.78 | 2024 | Libtayo |
| Rigel Pharmaceuticals, INC. | $22.96 | 2022 | |
| Morphosys, US INC. | $22.47 | 2022 | |
| Myovant Sciences INC. | $22.00 | 2021 | |
| Global Blood Therapeutics, INC. | $20.42 | 2022 | |
| Emd Serono, INC. | $14.13 | 2022 | |
| Genzyme Corporation | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grigorios Chrysofakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.